Home » Stocks » NRIX

Nurix Therapeutics, Inc. (NRIX)

Stock Price: $37.29 USD 1.68 (4.72%)
Updated Mar 1, 2021 1:52 PM EST - Market open
Market Cap 1.39B
Revenue (ttm) 17.82M
Net Income (ttm) -43.24M
Shares Out 15.67M
EPS (ttm) -2.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 1
Last Price $37.29
Previous Close $35.61
Change ($) 1.68
Change (%) 4.72%
Day's Open 35.95
Day's Range 35.76 - 38.41
Day's Volume 123,373
52-Week Range 15.21 - 52.38

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

First Investigational New Drug (IND) application cleared for NX-2127 in patients with relapsed and refractory B-cell malignancies

GlobeNewsWire - 1 month ago

Expansion of agreement results in an additional payment of $22 million to Nurix Expansion of agreement results in an additional payment of $22 million to Nurix

GlobeNewsWire - 2 months ago

Data support a planned clinical trial of NX-2127 in B-cell malignancies Data support a planned clinical trial of NX-2127 in B-cell malignancies

GlobeNewsWire - 3 months ago

SAN FRANCISCO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.  (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it wil...

GlobeNewsWire - 3 months ago

SAN FRANCISCO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it will...

GlobeNewsWire - 4 months ago

SAN FRANCISCO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), today announced that, based on his desire to lead Nurix's Scientific Advisory Board, Robert Tjian, Ph....

GlobeNewsWire - 4 months ago

Completed recent IPO raising approximately $238 .5 million in gross proceeds

GlobeNewsWire - 4 months ago

SAN FRANCISCO, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., (NASDAQ: NRIX), a company developing targeted protein modulation drugs, today announced the Company will be presentin...

Market Watch - 7 months ago

Nurix Therapeutics Inc. shares nrix fell 2.3% in their trading debut Friday, after pricing above the proposed price range.

About NRIX

Nurix Therapeutics, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader with immunomodulatory drug (IMiD) activity for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader without IMiD activity for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available... [Read more...]

Industry
Biotechnology
IPO Date
Jul 24, 2020
CEO
Dr. Arthur T. Sands
Employees
135
Stock Exchange
NASDAQ
Ticker Symbol
NRIX
Full Company Profile

Financial Performance

In 2020, NRIX's revenue was $17.82 million, a decrease of -42.73% compared to the previous year's $31.12 million. Losses were -$43.24 million, 99.3% more than in 2019.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for NRIX stock is "Buy." The 12-month stock price forecast is 52.20, which is an increase of 39.98% from the latest price.

Price Target
$52.20
(39.98% upside)
Analyst Consensus: Buy